Cronos Group Inc.
CRON
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $1.2B
$3.26
▲ 0.00%
P/E
17.98
Mkt Cap
$1.2B
52-Wk Range
$2.28–$3.61
52-Week Range
$2.28 - $3.61
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 31.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Diversified brand portfolio across hemp and cannabis segments
- Vertically integrated operations from cultivation to retail
- Established distribution network across e-commerce, retail, and wholesale channels
- International export capabilities and global market presence
Bear Case
2 risks
- Average volatility.
- Growth premium of 1.6x vs Large Cap Pharma peers. Elevated but may be justified by growth trajectory.
Growth
Revenue decline expected
Expanding legal cannabis market adoption across North America
Value
Growth premium of 1.6x vs Large Cap Pharma peers. Elevated but may be justified by growth trajectory.
Momentum
Strong
+17.7% over 3m
Quality
Strong
High-growth business (86% revenue growth, 45% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying CRON right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of $0.09 vs $0.01 consensus (+800.0% surprise). Revenue of $53.0M vs $44.2M expected (+19.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+800.0%
Revenue trend · last 8Q
—
—
+28%
+21%
+6%
+201%
+38%
+111%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$34.3M
$30.3M
$32.3M
$33.5M
$36.3M
$91.3M
$44.6M
$70.6M
Margins · last 8Q
Gross
40.3%
Operating
10.5%
Profit
45.5%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CRON stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related